Crispr Therapeutics Aghares (NASDAQ:CRSP) Reports Increase in Sellers; Strong Momentum for Short Players

The stock of Crispr Therapeutics Aghares (NASDAQ:CRSP) registered an increase of 0.51% in short interest. CRSP’s total short interest was 2.99 million shares in December as published by FINRA. Its up 0.51% from 2.97M shares, reported previously. With 718,200 shares average volume, it will take short sellers 4 days to cover their CRSP’s short positions. The short interest to Crispr Therapeutics Aghares’s float is 11.25%.

The stock decreased 1.16% or $0.42 during the last trading session, reaching $35.92. About 616,521 shares traded. CRISPR Therapeutics AG (NASDAQ:CRSP) has risen 183.99% since December 7, 2017 and is uptrending. It has outperformed by 168.37% the S&P500.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland. The company has market cap of $1.86 billion. The CRISPR/Cas9 technology allows for changes to genomic DNA. It currently has negative earnings. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies.

More notable recent CRISPR Therapeutics AG (NASDAQ:CRSP) news were published by: Seekingalpha.com which released: “CRISPR Therapeutics down 3% premarket on negative FT article – Seeking Alpha” on November 19, 2018, also Benzinga.com with their article: “22 Stocks Moving In Monday’s Pre-Market Session – Benzinga” published on November 19, 2018, Seekingalpha.com published: “Crispr Therapeutics: Buy The Secondary – Seeking Alpha” on January 15, 2018. More interesting news about CRISPR Therapeutics AG (NASDAQ:CRSP) were released by: Nasdaq.com and their article: “CRISPR THERAPTC (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher? – Nasdaq” published on November 07, 2018 as well as Nasdaq.com‘s news article titled: “Cronos (CRON) to Report Q3 Earnings: What’s in the Cards? – Nasdaq” with publication date: November 07, 2018.

CRISPR Therapeutics AG (NASDAQ:CRSP) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.